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Background: Evaluating the potential role of standardized uptake value (SUV) in patients 
with locally advanced, non-metastased, high-grade, extremity soft tissue sarcoma.  
Methods: Thirteen patients scheduled for hyperthermic isolated limb perfusion (ILP), referred 
for a 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)-scan were 
eligible. The SUV in the sarcoma lesion was calculated before and six weeks after ILP. After 
the second scan, surgical resection was performed. Survival data were assessed.  
Results: Univariate analysis showed prolonged overall survival in those with a low SUVmax 
value after perfusion (144 ± 8months) compared to those with a high SUVmax (33 ± 
8 months) (p=0.004), but SUV max was not an independent prognostic factor (p=0.08).  
Conclusion: Patients with a high grade locally advanced STS with a high SUVmax 
postperfusion showed a decreased overall survival compared to patients with a low SUVmax. 
The opportunities of SUV measurements in diagnosis and treatment evaluation of STS 
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Introduction 
Over the past thirty years there has been a tremendous progress in the local management of 
these malignancies. Improved developments in diagnostic imaging and surgical treatment 
with adjuvant radiotherapy are the cornerstones of this evolution: almost 90% of extremity 
STS can be treated today with limb salvage surgery with or without adjuvant radiation.1,2 For 
patients with primary irresectable STS, hyperthermic isolated limb perfusion (ILP) with 
Tumor Necrosis Factor alpha (TNF) and Melphalan became available in the early nineties. 
This treatment has resulted in a long term limb salvage rate of 82%.3 Survival of extremity-
STS-patients is not influenced by these limb salvage procedures.4 The 5-year survival rate of 
soft tissue sarcomas (STS) of the extremities is 60-70%.1,2 Identification of prognostic factors 
may allow the development of individualized strategies leading to improved results.  
A possible way to identificate prognostic factors is Positron Emission Tomography (PET). 
PET visualizes the uptake of radiolabeled tracers.5 18F-Fluorodeoxyglucose (FDG), a 
radiolabeled glucose analogue is a tracer that measures the glucose metabolism which is 
increased in cancer cells.6 An accelerated rate of glucose transport and an increased rate of 
glycolysis are among the most characteristic biochemical markers of malignant 
transformation.7 FDG uptake has been found to be associated with cell viability and 
particularly with cell proliferative activity.8-10 The currently most widely used radiotracer in 
oncology is FDG.11 A systematic review and meta-analysis indicated that FDG-PET can 
discriminate between benign and malignant soft tissue tumors and low and high-grade 
sarcomas based on the Standardized Uptake Value (SUV).12 SUV of PET assesses the degree 
of tracer accumulation. In patients with breast cancer, head and neck carcinoma, pancreatic 
cancer and lung cancer, high FDG uptake showed a significantly lower disease-free and 
overall survival. The SUVmean or SUVmax turned out to be significant prognostic factors in 
several univariate and multivariate analyses.7,13-19 However, studies have also been published 
where the SUV had no prognostic value with respect to disease-free or overall survival.17,20  
No studies evaluating consecutive values of FDG-uptake prior and after regional 
chemotherapy have been performed in patients with a soft tissue sarcoma of the extremity. 
The potential role of the SUV was analyzed in predicting relevant aspects of long-term 





Patients and Methods 
Patients 
All STS patients with a high grade STS in the extremity, more than 5 cm in diameter and 
without distant metastases, who where referred to Groningen University Medical Center from 
1991 to 1995 and who underwent a hyperthermic iolated limb perfusion (ILP) and FDG-PET 
imaging prior and 6 weeks post ILP were eligible for this study. The SUV in the sarcoma 
lesion was calculated before resection: the first FDG-PET before ILP and the second FDG-
PET after ILP. ILP of the affected limb was performed with TNF alpha and Melphalan and 
followed by delayed surgical resection.3,21 The histopathological response of ILP was 
standardized and scored according to the World Health Organisation (WHO) criteria.22 
Complete histopathological response (CR) was defined as disappearance of all measurable 
disease in the limb for longer than 4 weeks; partial response (PR) as regression of the tumor 
size by greater than 50% for longer than 4 weeks, no change (NC) as regression of less than 
50% of the tumor in the limb or progression of less than 25% for longer than 4 weeks. 
Extensive histopathologic examinations of the resected specimens were performed. The 
percentage of necrosis was estimated on the basis of macroscopic evaluation of necrotized 
tissue and histologic examination results of tissue surrounding the necrotic area, tissue 
without identifiable nuclei being considered necrotic. If clinically no tumor was detectable 
anymore (clinical CR) but resection of the tumor bed showed vital tumor cells, the final 
outcome was downgraded to a PR. A clinical PR could only be upgraded to a CR if histologic 
analysis showed 100% necrosis of the tumor remnant. Likewise, a clinical minimal regression 
of <50%, but still rendering the tumor resectable, could be upgraded to a PR if the tumor 
remnant was found to be necrotic for 50% or more. A clinical regression of >50% would 
qualify for a PR even if necrosis in the tumor remnant would be <50%, as >50% of the tumor 
mass had disappeared.23 The tumor was histopathological classified using the most recent 
World Health Organization's Classification of Tumors and graded according to the French 
grading system.24,25 In case of marginal resection margins postoperative radiotherapy (60-70 
Gy) was started 5-6 weeks after tumor resection. Patients were included in the study if they 
had a perfusion after the first PET and a resection after the 2nd PET. The medical records of 
these patients were reviewed and the following information was retrieved: age at the time of 
perfusion, sex, FDG-uptake prior to, and after ILP, characteristics of the sarcoma 
(localization, type, grade, percentage of necrosis after perfusion), limb salvage, period of 
follow-up, local recurrence of the tumor, disease free survival, overall survival and 
characteristics of the metastases if they occurred during follow-up (localization, time of 
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appearance). The technique of hyperthermic ILP with TNF ad Melphalan was extended 
described earlier.26  
 
Positron emission tomography 
FDG was routinely produced by a robotic system with a radiochemical purity of > 98% 
according to the procedure described by Hamacher et al.27 All PET scans were performed 
using a ECAT 951/31 PET camera (Siemens/CTI, Knoxville, TN). Patients fasted for at least 
6 hours prior to PET scanning. Serum glucose levels (FDG-PET) were measured and were all 
within normal range. After a 20-min transmission scan for attenuation correction, 300-350 
MBq of FDG was injected intravenously and dynamic images were acquired for 16 time 
frames for a total of 50 min (ten 0.5 min, three 5 min and three 10 min). 
 
PET data analysis 
To measure the standardized uptake value (SUV), the last three time frames were summed 
using standard ECAT software. A region of interest (ROI) was drawn around the tumor in all 
planes to establish the plane with maximum FDG. A threshold of 70% of the maximum pixel 
value within the tumor was used. In this plane, SUVmax and SUVmean were determined 
using the injected radioactivity, measured radioactivity and patient weight. (SUV = 
radioactivity concentration in tissue (Bq/kg) / (injected dose (Bq) / patient weight (kg)). In the 
post-ILP PET scans, this procedure was repeated.  
 
Statistics  
The clinical data of the patients were analyzed using the Statistical Package for the Social 
Sciences (SPSS) for Windows (Version 12.0; SPSS INC., Chicago, IL). For the survival 
analysis patients were divided into two groups based on the median SUVmax. The 
relationships between SUV and patients' characteristics were assessed by the Student's t-test 
or analysis of variance as appropriate. Survival data were analyzed using the Kaplan-Meier 
method and the differences in cumulative survival rate were assessed using the log-rank test. 
Univariate and multivariate analysis (Cox proportional hazard model) were performed to 
determine independent prognostic predictors. All variables with p<0.2 in the univariate 
analysis were entered in the multivariate analysis. All p-values are 2-tailed and considered 





Thirteen patients met the inclusion criteria; eight males and five females with median age of 
53 (range 18-80) years. The STS was located in the upper extremity in 1 patient and in the 
lower extremity in 12 patients. The histology of the sarcomas is presented in Table 1. 
 
 
Table 1 Histology and grade of the soft tissue sarcomas in this study 
 
Histology Grade 
Embryonal rhabdomyosarcoma 3 
Dedifferentiated liposarcoma 2 
Fibrosarcoma 3 
2X Synovial sarcoma 3, 3 
Malignant peripheral nerve sheath tumor 
(MPNST) 
2, 3 
Myxoid Chondrosarcoma 2 
Primitive neuroectodermal tumor (PNET) 3 
Angiosarcoma 3 
3X Pleomorphic undifferentiated sarcoma  2, 3, 3 
 
The median size of the tumor was 16.2 cm. Median pre perfusion SUVmax was 5.6 (range 
2.1-12.2) and median post perfusion SUVmax was 3.1 (range 0.9-12.2). The median follow-
up time after PET scanning was 65 (range 10-152) months. At last follow-up, five patients 
were alive and eight were dead as a result of the disease. During follow-up one patient 
developed a local recurrence and nine patients distant metastases. Characteristics of the 
patients’ sarcomas and SUVmax are summarized in Table 2. There were no significant 
differences in patient and sarcoma characteristics. 
Univariate survival-analysis for various patient characteristics is presented in Table 3. Patients 
with a high SUVmax after perfusion had a significant lower overall survival as compared to 
those with low SUVmax (33±8 months versus 144±8 months; p=0.0004) (Figure 1). We also 
performed a univariate analysis for disease free- and limb-survival but no significant findings 
were retrieved.  
Because of possible interrelation between prognostic factors, multivariate analysis was 
performed. All variables with p<0.2 in the univariate analysis were entered in the multivariate 
analysis: sex, metastases during treatment, local recurrence, pathological response, radicality 
of performed resection (microscopically radical (R0), macroscopically radical but 
microscopically irradical (R1) or macroscopically irradical (R2)), and SUVmax after 
perfusion. Multivariate Cox regression showed that SUVmax after perfusion did not have a 
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significant independent impact on survival (p=0.084), but a trend can be shown towards 
increased survival with lower SUVmax. 
 
 
Table 2 Characteristics and SUVmax in patients with soft tissue sarcoma of the extremities  
 













































































































































SE = standard error  






Table 3 Univariate Kaplan-Meier survival analysis: differences in survival (log-rank test)  
 
Variable  Patients 
N 
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Figure 1 Kaplan-Meier overall survival for STS patients with a high post perfusion SUVmax 































There i  an increased interest with respect to the potential of SUV-measurements with FDG-
PET in patients treated with combined modality treatment. This pilot study shows that 
SUVmax of FDG-PET after regional chemotherapy with isolated limb perfusion might be a 
predictor for survival in patients with locally advanced high grade soft tissue sarcoma of the 
extremity. Biological studies have shown a correlation between SUVmax and tumor 
cellularity, mitosis and level of Ki-67 (a proliferative marker) and a moderate correlation with 
tissue levels of p53 (a cell growth regulation product).19 Data in clinical studies suggest SUV 
to be an important prognostic factor, e.g. in patients with pancreatic, prostate, gastric cancer, 
head and neck and non-small-cell lung cancer and melanoma.5,7,16,28-30  
In a selective group consisting of only high-grade sarcomas of the extremities without 
metastatic disease treated with regional chemotherapy through ILP we found that SUVmax 
was an independent predictor for survival in univariate analysis. A study in patients with bone 

















and soft tissue sarcoma (n=209) showed after a mean follow up of 19 months that SUVmax 
was a statistically significant independent predictor of patient survival.19 We can support this 
result with our findings reported after a longer period of follow up and in a less heterogeneous 
but smaller group as only high grade soft tissue sarcomas in the extremities were considered 
and the type of treatment was more standardized. Studies with more patients are needed to 
affirm the finding of both biological imaging studies. 
 
Conclusion 
Biological imaging with FDG-PET opens new frontiers in treatment evaluation of cancer 
treatment. In this pilot study patients with a high grade locally advanced STS with a high 
SUVmax postperfusion showed a decreased overall survival in univariate analysis compared 
to patients with a low SUVmax. The opportunities of SUV measurements in diagnosis and 
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